RxDoctor Payments Data

Sandhya Shukla, MD

Gastroenterology · Brick, NJNPI 1821220336

Payments from drug & device makers

$9,453in general payments, 2019–2025

Across 556 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$1K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$774
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$766
  • Madrigal Pharmaceuticals$583
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Travel & lodging$1,06211%
  • Food & beverage$8,32488%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,453 in reported general payments places this provider in the 80th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$174,523
Medicare patients
762
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$194,790
XifaxanRifaximin68$181,020
LinzessLinaclotide59$48,706
ZenpepLipase/Protease/Amylase18$25,805
Mesalamine35$13,298
Sucralfate74$9,316
MotegrityPrucalopride Succinate14$8,904
Mesalamine ErMesalamine25$8,275
Famotidine399$5,445
Pantoprazole Sodium323$3,917
CholestyramineCholestyramine (With Sugar)56$3,774
Lactulose45$1,095
Cholestyramine LightCholestyramine17$1,013
Omeprazole53$998
Budesonide DrBudesonide17$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$766$181,02068 claims
AbbVieLinzess$1,799$48,70659 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$353$8,90414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →